Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer |
| |
| Authors: | Claudia Fumarola Mara A. Bonelli Pier Giorgio Petronini Roberta R. Alfieri |
| |
| Affiliation: | Unit of Experimental Oncology, Clinical and Experimental Medicine Department, University of Parma, Via Volturno 39, 43126 Parma, Italy |
| |
| Abstract: | While PI3K/AKT/mTOR pathway is altered in a variety of cancers including non small cell lung cancer, abnormalities in this pathway are more common in squamous cell lung carcinoma than in adenocarcinoma of the lung. Moreover, aberrant activation of PI3K/AKT/mTOR pathway is one of the mechanisms of acquired resistance to EGFR-TK inhibitors in patients with adenocarcinoma carrying EGFR activating mutations. |
| |
| Keywords: | AE, adverse event CR, complete response EGFR, epidermal growth factor receptor MTD, maximum tolerated dose NSCLC, non small cell lung cancer ORR, overall response rate OS, overall survival mTOR, mammalian target of rapamycin PFS, progression free survival PI3K, phosphatidylinositol 3-kinase PR, partial response RTK, receptor tyrosine kinase SQCLC, squamous cell carcinoma SD, stable disease TKI, tyrosine kinase inhibitor |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
